154 related articles for article (PubMed ID: 38524636)
1. Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study.
Almutair A; Almulhem B
Front Endocrinol (Lausanne); 2024; 15():1294264. PubMed ID: 38524636
[TBL] [Abstract][Full Text] [Related]
2. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
3. Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database.
Warncke K; Kummer S; Raile K; Grulich-Henn J; Woelfle J; Steichen E; Prinz N; Holl RW
J Clin Endocrinol Metab; 2019 Mar; 104(3):845-855. PubMed ID: 30535056
[TBL] [Abstract][Full Text] [Related]
4. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
5. Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3).
Becker M; Galler A; Raile K
Pediatrics; 2014 Mar; 133(3):e775-9. PubMed ID: 24567025
[TBL] [Abstract][Full Text] [Related]
6. Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.
Terakawa A; Chujo D; Yasuda K; Ueno K; Nakamura T; Hamano S; Ohsugi M; Tanabe A; Ueki K; Kajio H
Medicine (Baltimore); 2020 Aug; 99(35):e21939. PubMed ID: 32871938
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
[TBL] [Abstract][Full Text] [Related]
8. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
9. A Case of Diabetes Mellitus Type MODY5 as a Feature of 17q12 Deletion Syndrome.
Yaşar Köstek H; Özgüç Çömlek F; Gürkan H; Özkayın EN; Tütüncüler Kökenli F
J Clin Res Pediatr Endocrinol; 2024 May; 16(2):205-210. PubMed ID: 36511482
[TBL] [Abstract][Full Text] [Related]
10. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
12. A case of digenic maturity onset diabetes of the young with heterozygous variants in both HNF1Α and HNF1Β genes.
Patouni K; Cinek O; Pruhova S; Elblova L; Xatzipsalti M; Sertedaki A; Vazeou A
Eur J Med Genet; 2021 Sep; 64(9):104264. PubMed ID: 34161864
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
14. [Clinical parameters for molecular testing of Maturity Onset Diabetes of the Young (MODY)].
Datz N; Nestoris C; von Schütz W; Danne T; Driesel AJ; Maringa M; Kordonouri O
Dtsch Med Wochenschr; 2011 May; 136(21):1111-5. PubMed ID: 21590629
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
16. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
[TBL] [Abstract][Full Text] [Related]
17. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
[TBL] [Abstract][Full Text] [Related]
18. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
Andersen A; Knop FK; Vilsbøll T
Drugs; 2021 Jun; 81(9):1003-1030. PubMed ID: 33964002
[TBL] [Abstract][Full Text] [Related]
19. Semaglutide in Cystic Fibrosis-Related Diabetes.
Gnanapragasam H; Mustafa N; Bierbrauer M; Andrea Providence T; Dandona P
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32232400
[TBL] [Abstract][Full Text] [Related]
20. Onset of type 1 diabetes mellitus in two patients with maturity onset diabetes of the young.
Maltoni G; Zucchini S; Scipione M; Mantovani V; Salardi S; Cicognani A
Pediatr Diabetes; 2012 Mar; 13(2):208-12. PubMed ID: 21696527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
